Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort descending
Kineret anakinra Still's disease Withdrawn
Tysabri natalizumab Multiple Sclerosis, relapsing-remitting Withdrawn
TBC risperidone Schizophrenia, adults Suspended
TBC ruxolitinib atopic dermatitis Active
Prevymis letermovir Cytomegalovirus infection (CMV), prophylaxis Withdrawn
Isturisa osilodrostat Endogenous Cushing’s syndrome Suspended
Winlevi clascoterone Acne vulgaris Withdrawn
Tafinlar-Mekinist dabrafenib trametinib Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation Pending
TBC pegcetacoplan Geographic atrophy secondary to age-related macular degeneration Active
Nurtec ODT rimegepant Migraine, prevention Withdrawn